Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes

Xiaoqing He1, Hong Kan, Lu Cai

  • 1Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgantown, WV, USA.

Insights

Nuclear factor erythroid 2-related factor 2 (Nrf2) protects heart cells from high glucose-induced oxidative stress. Nrf2 deficiency worsens reactive oxygen species (ROS) production and apoptosis in cardiomyocytes, highlighting its critical role in diabetic heart defense.

Area of Science:

  • Cardiovascular Biology
  • Oxidative Stress Research
  • Molecular Cardiology

Background:

  • High glucose levels in diabetes induce reactive oxygen species (ROS) in cardiomyocytes, potentially leading to cardiomyopathy.
  • Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key regulator of the cellular antioxidant response to oxidative stress.

Purpose of the Study:

  • To investigate the role of Nrf2 in protecting cardiomyocytes against high glucose-induced oxidative damage.
  • To determine Nrf2's function in maintaining cardiomyocyte health under diabetic conditions.

Main Methods:

  • Utilized Nrf2 wild-type (WT) and knockout (KO) primary neonatal and adult cardiomyocytes.
  • Assessed reactive oxygen species (ROS) production, apoptosis levels, and gene expression (Nqo1, Ho1) under varying glucose concentrations.
  • Examined cardiomyocyte function and sensitivity to mitochondrial inhibitors.

Main Results:

  • Nrf2 KO cardiomyocytes exhibited significantly higher basal ROS production, which was markedly exacerbated by high glucose.
  • High glucose induced greater apoptosis in Nrf2 KO cells compared to WT cells.
  • Nrf2 deficiency impaired the expression of antioxidant genes (Nqo1, Ho1) and compromised cardiomyocyte function.

Conclusions:

  • Nrf2 is a critical regulator of antioxidant defense in cardiomyocytes, protecting against high glucose-induced oxidative stress and apoptosis.
  • Nrf2 plays a vital role in maintaining normal and diabetic heart function by controlling cytoprotective gene expression.
  • These findings establish Nrf2 as a key therapeutic target for diabetic cardiomyopathy.